Akcea Therapeutics (AKCA) Lifted to Hold at BidaskClub

Akcea Therapeutics (NASDAQ:AKCA) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other research analysts have also recently issued reports on the company. Zacks Investment Research cut Akcea Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 target price (up previously from $19.00) on shares of Akcea Therapeutics in a research report on Tuesday, November 7th. Finally, Cowen reaffirmed a “buy” rating on shares of Akcea Therapeutics in a research report on Tuesday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $22.75.

Akcea Therapeutics (NASDAQ AKCA) opened at $17.90 on Friday. The stock has a market capitalization of $1,190.00 and a P/E ratio of -4.54. Akcea Therapeutics has a 1 year low of $8.10 and a 1 year high of $31.23.

Akcea Therapeutics (NASDAQ:AKCA) last announced its earnings results on Monday, November 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.03. analysts predict that Akcea Therapeutics will post -1.98 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of AKCA. Strs Ohio bought a new stake in Akcea Therapeutics during the third quarter worth $118,000. Nationwide Fund Advisors bought a new stake in Akcea Therapeutics during the third quarter worth $209,000. Candriam Luxembourg S.C.A. bought a new stake in Akcea Therapeutics during the third quarter worth $5,314,000. New York State Common Retirement Fund bought a new stake in Akcea Therapeutics during the third quarter worth $810,000. Finally, Rhumbline Advisers bought a new stake in Akcea Therapeutics during the third quarter worth $353,000. Institutional investors and hedge funds own 26.04% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Akcea Therapeutics (AKCA) Lifted to Hold at BidaskClub” was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3146801/akcea-therapeutics-akca-lifted-to-hold-at-bidaskclub.html.

Akcea Therapeutics Company Profile

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.